Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.75 |
| ▸ | GSK3A | P49840 | 4/20 | 0.73 |
| ▸ | PRKCA | P17252 | 2/20 | 0.68 |
| ▸ | RGS4 | P49798 | 11/20 | 0.62 |
| ▸ | RGS8 | P57771 | 11/20 | 0.62 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.62 |
| ▸ | CDK1 | P06493 | 1/20 | 0.62 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.62 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23763654 | 0.86 | RGS4 (0.57) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL23763548 | 0.86 | GSK3B (0.77) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL2107561 | 0.86 | GSK3B (1.00) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL2107216 | 0.85 | GSK3B (1.00) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL23763500 | 0.84 | GSK3B (0.77) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL28891753 | 0.84 | GSK3B (0.75) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL23763497 | 0.84 | GSK3B (0.75) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL13562490 | 0.82 | RGS4 (0.75) | GSK3BGSK3APRKCARGS4RGS8 | |
| Krm-7777 SCHEMBL3384141 | 0.81 | GSK3B (1.00) | GSK3BGSK3APRKCARGS4RGS8 | |
| SCHEMBL28959427 | 0.81 | GSK3B (0.69) | GSK3BGSK3APRKCARGS4RGS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125667-A1 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | US GOV VETERANS AFFAIRS (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125667-A1 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | US GOV VETERANS AFFAIRS (US) | 2023-04-27 | — | — | US | disclosed |
| WO-2021163572-A1 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES; AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | BOWROJU SURESH KUARM (US) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125667-A1 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | BRCA1, MTPN, MUSK | GSK3B 1208/4885GSK3A 1429/4885PRKCA 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.